Michael P. Duggan, Evangelos D. Katsanos, Hassan Hamandi. The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. // Journal of Pediatric Gastroenterology and Nutrition. – 2026. – DOI: 10.1002/jpn3.70534. – URL: https://onlinelibrary.wiley.com/doi/10.1002/jpn3.70534?af=R
Michael P. Duggan, Evangelos D. Katsanos, & Hassan Hamandi (2026). The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70534
Michael P. Duggan, et al. “The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease.” Journal of Pediatric Gastroenterology and Nutrition, 2026. doi:10.1002/jpn3.70534.
@article{Duggan2026,
title = {The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease},
author = {Duggan, Michael P. and Katsanos, Evangelos D. and Hamandi, Hassan},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70534},
url = {https://onlinelibrary.wiley.com/doi/10.1002/jpn3.70534?af=R}
}